Recently, ADAM17 was discovered as a crucial mediator of resistance to radiotherapy.
Radiotherapy can induce a dose-dependent increase of furin-mediated cleavage of the ADAM17 proform to active ADAM17, which results in enhanced ADAM17 activity in vitro and in vivo.